Ozcifci, Guzin http://orcid.org/0000-0002-4774-9284
Aydin, Tahacan http://orcid.org/0000-0002-8125-4808
Atli, Zeynep http://orcid.org/0000-0002-2959-0978
Balkan, Ilker Inanc http://orcid.org/0000-0002-8977-5931
Tabak, Fehmi http://orcid.org/0000-0001-8632-2825
Oztas, Mert http://orcid.org/0000-0002-4077-1374
Ozguler, Yesim http://orcid.org/0000-0002-2082-4715
Ugurlu, Serdal http://orcid.org/0000-0002-9561-2282
Hatemi, Gulen http://orcid.org/0000-0002-1952-1135
Melikoglu, Melike http://orcid.org/0000-0003-0253-8368
Fresko, Izzet http://orcid.org/0000-0002-8914-9690
Hamuryudan, Vedat http://orcid.org/0000-0001-6625-1652
Seyahi, Emire http://orcid.org/0000-0003-4965-2918
Article History
Received: 21 October 2021
Accepted: 13 November 2021
First Online: 25 November 2021
Declarations
:
: Guzin Ozcifci, Tahacan Aydin, Zeynep Atli, Ilker Inanc Balkan, Mert Oztas, Yesim Ozguler, Melike Melikoglu, Izzet Fresko and Vedat Hamuryudan declare that they have no conflict of interest. Fehmi Tabak, has received honoraria, consulting or speaker fees from GSK, MSD, AbbVie and Gilead. Serdal Ugurlu has received honoraria, consulting or speaker fees from Novartis, Pfizer, Lilly and Celltrion. Gulen Hatemi has received research grant from Celgene, honoraria consulting or speaker fees from AbbVie, Amgen, Celgene, Lilly, Novartis and UCB Pharma. Emire Seyahi has received honoraria, consulting or speaker fees from Novartis, Pfizer, AbbVie and Gilead.
Free to read: This content has been made available to all.